Slayback Pharma
Money and medicine on ECG

Former Dr. Reddy’s exec-led Slayback Pharma raises $60 mn from KKR

2 months ago

Slayback Pharma, LLC, a privately held pharmaceutical company founded by a former executive of Indian drugmaker Dr. Reddy’s Laboratories Ltd, has raised $60 million (around Rs 400 crore) from global investment firm KKR, it said in a statement.

The financing will help Slayback accelerate the development of its portfolio of generic and specialty pharmaceutical products, KKR said in the statement.

Slayback was founded in 2011 by Ajay Singh, who was vice president of strategy, portfolio and business development at Dr. Reddy’s for its North American generics division, a spokesperson of the firm said.

The firm works closely with active pharmaceutical ingredient (API) suppliers and contract manufacturing organisations (CMOs) based in India (though not exclusively), in addition to employing formulation and technical staff in India, the spokesperson said without divulging further details.

As part of the transaction, Ali Satvat and Neel Varshney from KKR will join Slayback’s board.

“In addition to being a highly regarded long-term capital partner, KKR with its legacy in the pharmaceutical space and its experience in scaling businesses will help Slayback achieve the next level of growth,” said Ajay Singh who is also CEO of Slayback.

KKR said the investment is part of the firm’s healthcare strategy.

The investment in Slayback builds upon KKR’s experience in the pharmaceutical value chain, including investments in Jazz Pharmaceuticals, Arbor Pharmaceuticals, Coherus BioSciences, BridgeBio Pharma, PRA Health Sciences, Capsugel and Walgreens Boots Alliance, it said.

In July 2016, China’s Shanghai Fosun Pharmaceutical (Group) Co. Ltd said will acquire a majority stake in Hyderabad-based Gland Pharma Ltd for up to $1.26 billion (Rs 8,440 crore), giving KKR an exit.

Like this report? Sign up for our daily newsletter to get our top reports.


View Comments
Dr Reddy's to buy eight generic drugs in US for $350 mn

Dr Reddy’s to buy eight generic drugs in US for $350 mn

TEAM VCC 9 months ago
Dr Reddy’s Laboratories Ltd said on Saturday it has agreed to buy eight generic drugs in the US from Teva Pharmaceutical and Allergan Plc for...
Dr. Reddy's acquires six consumer healthcare OTC brands in US

Dr. Reddy’s acquires six consumer healthcare OTC brands in US

TEAM VCC 10 months ago
Dr. Reddy’s Laboratories Ltd has acquired a portfolio of half a dozen over-the-counter (OTC) drug brands from American drugmaker Ducere Pharma to enter the branded...
Cipla, Aurobindo Pharma to acquire drugs from Teva

Cipla, Aurobindo Pharma to acquire drugs from Teva

Ranjani Raghavan 8 months ago
Cipla Ltd and Aurobindo Pharma Ltd have agreed to acquire some generic drugs from Teva Pharmaceutical Industries Ltd in the US, as the Indian generic...
No Comments

Former Dr. Reddy’s exec-led Slayback Pharma raises $60 mn from KKR

Powered by WordPress.com VIP